Earnings Roundup: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)


Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) moved down -9.34% and closed its last trading session at $4.27. This Medical Sector stock currently has the Market Capitalization of 587.72 Million. The Average Volume for the stock is measured as 1.69 Million. The Stock has a 52-Week High of $10.06 and 52-Week Low of $3.78 following the dates, it touched its 52-Week High on Jun 9, 2016 and 52-Week Low on Nov 3, 2016. Currently, the Return on Assets value for the trailing twelve months is -9.2% with the Return on Equity and Return on Investment of -9.5% and -3.4% respectively. This firm currently has YTD (year to date) performance of 3.39 Percent which is awesome. The Short Ratio for the stock is 6.29.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.3. The TTM operating margin is 0 percent.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reports its Earnings on Thu 23 Feb (In 7 Days). The estimated EPS for the current quarter is said to be $-0.18. Following Earnings result, share price were DOWN 15 times out of last 28 Qtrs. The stock has reduced about -22% since it reported its last earnings. The Closing price of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) at Last Earnings was $6.04 as compared to the previous closing price of $4.71. The Predicted Move on the 7th day after Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will release its earnings at about 8%.

By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) beats earnings by 75%, The Stock Missed Earnings  2  times and has met earnings  1 times.

Earnings History:

We will discuss the past Quarters Earnings below:

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) reported its previous quarter on 11/03/2016 where it reported the Actual Earnings of $-0.15. The Closing price before the company posted its earnings was $6.04. The Stock declined on the very next day of earnings and maintained its stock price at $4.32 by showing a % change of -28.48 percent from its previous closing price. The Next Day Volume after Earnings was reported as 15.67 Million. On the 7th day After Earnings Report, the stock hit its share price as $4.52 by showing -25.17% decrease from the Stock price Before Earnings were reported.

On 08/04/2016, the stock reported the EPS of $-0.14 where Analysts were projecting the EPS to be $-0.15 showing a difference of $0.01. Thus Surprise Factor was there with 6.7 percent. Before Earnings Announcement on 08/04/2016, the firm had its stock price of $8.55. And immediately on the next day after earnings announcement, the stock inclined 6.67% and closed its trading session at $9.12. On 7th Day after earnings release, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) surged to 3.51% from $8.55 to $8.85.

Company Profile:

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor, which has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor that is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and one additional systemic ultra-rare disease; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally; and license and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.